Lyophilisation and filling capabilities at the facility include aseptic filling of highly potent, cytotoxic and non-cytotoxic liquid and dry-powder vials, sterile crystallisation of cytotoxic active pharmaceutical ingredients and lyophilisation cycle development.
-
The Baxter cytotoxic contract manufacturing facility has over 20 years of... -
Cytotoxic agents are one of the most highly sensitive drugs to manage and... -
The facility manufactures parental products in liquid, crystallite, dry... -
Lyophilisation and filling capabilities at the facility include aseptic...
Twitter